Lira-cel employs CER-T technology, a distinct CAR-T modality that uses the natural ligand FSH to engage FSHR, differentiating it from antibody-based approaches and is underpinned by collaboration with Duke-Associated researchers via Dr. Jose Conejo-Garcia.

Investors are advised not to treat the forward-looking statements as guarantees of future performance.

Media contact for inquiries is Mike Catelani, with provided email and phone details.

Market context accompanies the release, noting recent ANIX trading patterns and a trend of negative moves after positive clinical or IP updates, framed as increasing scientific visibility for Anixa.

Dr. Jose Conejo-Garcia, a Duke University immunology professor and co-inventor of Anixa’s FSHR-mediated CAR-T technology, will keynote the SCTR 2026 Retreat on March 6, 2026.

Dr. Conejo-Garcia’s work with FSHR-mediated CAR-T underpins lira-cel and will be highlighted at the retreat.

The keynote will cover Anixa’s ongoing Phase 1 trial of liraltagene autoleucel (lira-cel) targeting FSHR in recurrent ovarian cancer, enrolling adult women after two or more prior therapies.

Lira-cel targets FSHR expressed on ovarian cells, tumor vasculature, and some cancer cells while sparing healthy tissue.

Dr. Conejo-Garcia’s presentation will discuss the discovery of the FSHR-mediated CAR-T approach and its progression through Anixa’s lira-cel program.

Anixa Biosciences, a clinical-stage biotech focused on cancer treatment and prevention, is advancing lira-cel, a CER-T CAR-T therapy developed with Moffitt Cancer Center, alongside a portfolio of Cleveland Clinic–developed vaccines licensed to Anixa with royalties and revenues outlined in collaboration agreements.

Cleveland Clinic–originated vaccines for breast and ovarian cancer are part of Anixa’s portfolio, licensed with revenue-sharing terms detailed in their partnerships.

The press release includes forward-looking statements with standard risk disclosures, noting results may differ from expectations and that the company does not promise updates beyond legal requirements.